NCT07095686View on ClinicalTrials.gov

Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 2, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

nL-CHCHD-001

Personalized antisense oligonucleotide

Trial Locations (1)

10032

Columbia University, Irving Medical Center, New York

All Listed Sponsors
collaborator

Columbia University

OTHER

lead

n-Lorem Foundation

OTHER